These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1060 related items for PubMed ID: 22309269

  • 1. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [Abstract] [Full Text] [Related]

  • 2. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S, Vali AM, Rezaie M.
    Int J Pharm; 2008 Apr 02; 353(1-2):251-9. PubMed ID: 18191511
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C, Cui J, Wang C, Li Y, Zhang L, Xiu X, Li Y, Wei N, Zhang L, Wang P.
    J Pharm Pharmacol; 2011 Jun 02; 63(6):765-73. PubMed ID: 21585373
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct 02; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 8. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
    Li CL, Cui JX, Wang CX, Zhang L, Li YH, Zhang L, Xiu X, Li YF, Wei N.
    Int J Pharm; 2010 May 31; 391(1-2):230-6. PubMed ID: 20214962
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 11. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS, Nawata K, Shimizu T, Ishida T, Kiwada H.
    Int J Pharm; 2013 Nov 01; 456(1):235-42. PubMed ID: 23928149
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
    Huang FY, Mei WL, Li YN, Tan GH, Dai HF, Guo JL, Wang H, Huang YH, Zhao HG, Zhou SL, Li L, Lin YY.
    Eur J Cancer; 2012 Sep 01; 48(14):2260-9. PubMed ID: 22257793
    [Abstract] [Full Text] [Related]

  • 14. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
    Yuan ZP, Chen LJ, Fan LY, Tang MH, Yang GL, Yang HS, Du XB, Wang GQ, Yao WX, Zhao QM, Ye B, Wang R, Diao P, Zhang W, Wu HB, Zhao X, Wei YQ.
    Clin Cancer Res; 2006 May 15; 12(10):3193-9. PubMed ID: 16707620
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.
    Cancer Chemother Pharmacol; 2010 Nov 15; 66(6):1173-84. PubMed ID: 20661737
    [Abstract] [Full Text] [Related]

  • 16. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Xiu X, Li Y, Wei N.
    J Pharm Sci; 2011 Jul 15; 100(7):2835-48. PubMed ID: 21305545
    [Abstract] [Full Text] [Related]

  • 17. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T, Atobe K, Wang X, Kiwada H.
    J Control Release; 2006 Oct 27; 115(3):251-8. PubMed ID: 17045355
    [Abstract] [Full Text] [Related]

  • 18. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
    Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD.
    Cancer Res; 2000 Jul 01; 60(13):3389-93. PubMed ID: 10910044
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation.
    Gill KK, Nazzal S, Kaddoumi A.
    Eur J Pharm Biopharm; 2011 Oct 01; 79(2):276-84. PubMed ID: 21575719
    [Abstract] [Full Text] [Related]

  • 20. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
    Li C, Zhao X, Wang Y, Yang H, Li H, Li H, Tian W, Yang J, Cui J.
    Int J Pharm; 2013 Feb 25; 443(1-2):17-25. PubMed ID: 23318366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.